Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma

References

• Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27(4):511–518.
   PubMed Web of Science ®Google Scholar
• Abrahamsson A, Dahle N, Jerkeman M. Marked improvement of overall survival in mantle cell lymphoma: a population -based study from the swedish lymphoma registry. Leuk Lymphoma. 2011;52(10):1929–1935.
   PubMed Web of Science ®Google Scholar
• Smith A, Roman E, Appleton S, et al. Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK’s Haematological Malignancy Research Network (HMRN). Br J Haematol. 2018;181(2):215–228.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–565.
   PubMed Web of Science ®Google Scholar
• Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the european mantle-cell lymphoma network. J Clin Oncol. 2014;32(13):1338–1346.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;150(2):200–208.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3(2):185–197.
   PubMed Web of Science ®Google Scholar
• Hoster E, Rosenwald A, Berger F, et al. Prognostic value of ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the european mantle cell lymphoma network. J Clin Oncol. 2016;34(12):1386–1394.
   PubMed Web of Science ®Google Scholar
• de Jong D, Rosenwald A, Chhanabhai M, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications- a study from the lunenburg lymphoma biomarker consortium. J Clin Oncol. 2007;25(7):805–812.
   PubMed Web of Science ®Google Scholar
• Scott DW, Abrisqueta P, Wright GW, et al. New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies. J Clin Oncol. 2017;35(15):1668–1677.
   PubMed Web of Science ®Google Scholar
• Rauert-Wunderlich H, Mottok A, Scott DW, et al. Validation of the MCL35 gene expression proliferation assay in randomized trials of the european mantle cell lymphoma network. Br J Haematol. 2019;184(4):616–624.
   PubMed Web of Science ®Google Scholar
• Jung D, Jain P, Yao Y, et al. Advances in the assessment of minimal residual disease in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):127.
   PubMed Web of Science ®Google Scholar
• He JS, Chen X, Wei GQ, et al. Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China. Medicine (Baltimore). 2019;98(1):e13741.
   PubMed Web of Science ®Google Scholar
• Kridel R, Meer B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012;119(9):1963–1971.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Rossi D, Rinaldi A, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020;105(6):1604–1612.
   PubMed Web of Science ®Google Scholar
• Malarikova D, Berkova A, Obr A, et al. Concurrent TP53 and CDKN2A gene aberrations in newly diagnosed mantle cell lymphoma correlate with chemoresistance and call for innovative upfront therapy. Cancers (Basel). 2020;12(8):E2120.
   PubMed Web of Science ®Google Scholar
• Husby S, Ralfkiaer U, Garde C, et al. miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. Blood. 2015;125(17):2669–2677.
   PubMed Web of Science ®Google Scholar
• Zhou K, Feng X, Wang Y, et al. miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11. Exp Hematol. 2018;58(27):e1.
   Google Scholar
• Puente XS, Jares P, Campo E. Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood. 2018;131(21):2283–2296.
   PubMed Web of Science ®Google Scholar
• Rodrigues JM, Nikkarinen A, Hollander P, et al. Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. Br J Haematol. 2021;193(3):520–531.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Goy A, Wu T, Hansen E, et al. Impact of Charlson Comorbidity Index (CCI) and Refining the MIPI Index in Mantle Cell Lymphoma (MCL). Blood. 2016;128(22):2973.
   Web of Science ®Google Scholar
• Albano D, Laudicella R, Ferro P, et al. The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: an Italian Multicentric Study. Cancers (Basel). 2019;11(12):E1831.
   PubMed Web of Science ®Google Scholar
• Bailly C, Carlier T, Berriolo-Riedinger A, et al. Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. Haematologica. 2020;105(1):e33–e36.
   PubMedGoogle Scholar
• Mato AR, Svoboda J, Feldman T, et al. Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer. 2012;118(14):3565–3570.
   PubMed Web of Science ®Google Scholar
• Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012;158(3):355–362.
   PubMed Web of Science ®Google Scholar
• Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016;388(10044):565–575.
   PubMed Web of Science ®Google Scholar
• Pott C, Hoster E, Delfau-Larue MH, et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood. 2010;115(16):3215–3223.
   PubMed Web of Science ®Google Scholar
• Bond D, Switchenck J, Maddocks K, et al. Outcomes following early relapse in patients with mantle cell lymphoma. Blood. 2020;134(Supplement_1):753.
   Google Scholar
• Navarro A, Beà S, Jares P, et al. Molecular Pathogenesis of Mantle Cell Lymphoma. Hematol Oncol Clin North Am. 2020;34(5):795–807.
   PubMed Web of Science ®Google Scholar
• Salaverria I, Zettl A, Beà S, et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol. 2007;25(10):1216–1222.
   PubMed Web of Science ®Google Scholar
• Greenwell IB, Staton AD, Lee MJ, et al. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer. 2018;124(11):2306–2315.
   PubMed Web of Science ®Google Scholar
• Schraders M, Pfundt R, Straatman HM, et al. Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. Blood. 2005;105(4):1686–1693.
   PubMed Web of Science ®Google Scholar
• Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130(17):1903–1910.
   PubMed Web of Science ®Google Scholar
• Obr A, Klener P, Furst T, et al. A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. Br J Haematol. 2020;191(5):e103–e106.
   PubMed Web of Science ®Google Scholar
• Clot G, Jares P, Giné E, et al. A gene signature that distinguishes conventional and leukemic non-nodal mantle cell lymphoma helps predict outcome. Blood. 2018;132(4):413–422.
   PubMed Web of Science ®Google Scholar
• Delfau-Larue MH, Klapper W, Berger F, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126(5):604–611.
   PubMed Web of Science ®Google Scholar
• Wang K, Nahas MK, Yelensky R, et al. Novel chromatin modifying gene alterations and significant survival association of ATM and P53 in mantle cell lymphoma. Blood. 2014;124(21):3033.
   Web of Science ®Google Scholar
• Jain P, Wang M. Blastoid mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34(5):941–956.
   PubMed Web of Science ®Google Scholar
• Beà S, Amador V. Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma. Curr Oncol Rep. 2017;19(6):43.
   PubMed Web of Science ®Google Scholar
• Beekman R, Amador V, Campo E. SOX11, a key oncogenic factor in mantle cell lymphoma. Curr Opin Hematol. 2018;25(4):299–306.
   PubMed Web of Science ®Google Scholar
• Nadeu F, Martin-Garcia D, Clot G, et al. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020;136(12):1419–1432.
   PubMed Web of Science ®Google Scholar
• Queirós AC, Beekman R, Vilarrasa-Blasi R, et al. Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage. Cancer Cell. 2016;30(5):806–821.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantlecell lymphoma. J Clin Oncol. 2009;27(8):1209–1213.
   PubMed Web of Science ®Google Scholar
• Lee C, Watch MP. Wait in mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34(5):837–847.
   PubMed Web of Science ®Google Scholar
• Ye H, Desai A, Zeng D, et al. Smoldering mantle cell lymphoma. J Exp Clin Cancer Res. 2017;36(1):185.
   PubMedGoogle Scholar
• Palomero J, Vegliante MC, Rodríguez ML, et al. SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood. 2014;124(14):2235–2247.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Williams ME. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol. 2002;33(1):7–20.
   PubMed Web of Science ®Google Scholar
• Abrisqueta P, Scott DW, Slack GW, et al. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol. 2017;28(10):2489–2495.
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209–1213.
   PubMed Web of Science ®Google Scholar
• Cohen JB, Han X, Jemal A, et al. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. Cancer. 2016;122(15):2356–2363.
   PubMed Web of Science ®Google Scholar
• McCulloch R, Rule S. What is the optimal initial management of the younger mantle cell lymphoma patient. Best Pract Res Clin Haematol. 2018;31(1):90–98.
   PubMed Web of Science ®Google Scholar
• Jain P, Dreyling M, Seymour JF, et al. High-risk mantle cell lymphoma: definition, current challenges, and management. J Clin Oncol. 2020;38(36):4302–4316.
   PubMed Web of Science ®Google Scholar
• Wu H, Wang J, Zhang X, et al. Survival trends in patients under age 65 years with mantle cell lymphoma, 1995-2016: a SEER-Based Analysis. Front Oncol. 2020;10:588314.
   PubMedGoogle Scholar
• Chihara D, Cheah CY, Westin JR, et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD anderson cancer center. Br J Haematol. 2016;172(1):80–88.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Ponzoni M, Ferreri AJ, et al. Mantle cell lymphoma. Crit Rev Oncol Hematol. 2012;82(1):78–101.
   PubMed Web of Science ®Google Scholar
• Cavalli F. Bortezomib-based therapy for mantle-cell lymphoma. N Engl J Med. 2015;372(23):2271.
   PubMedGoogle Scholar
• Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Flinn IW, van der Jagt R, Kahl B, et al. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: results of the BRIGHT 5-Year Follow-Up Study. J Clin Oncol. 2019;37(12):984–991.
   PubMed Web of Science ®Google Scholar
• Visco C, Chiappella A, Nassi L, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from fondazione italiana linfomi. Lancet Haematol. 2017;4(1):e15–e23.
   PubMed Web of Science ®Google Scholar
• Ruan J, Leonard JP. Lenalidomide plus rituximab for mantle-cell lymphoma. N Engl J Med. 2016;374(8):793.
   PubMed Web of Science ®Google Scholar
• Villa D, Sehn LH, Savage KJ, et al. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma. Blood Adv. 2020;4(15):3486–3494.
   PubMed Web of Science ®Google Scholar
• Smith M, Jegede O, Parekh S, et al. Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL). Blood. 2019;134(Supplement_1):751.
   Web of Science ®Google Scholar
• Lacasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood. 2012;119(9):2093–2099.
   PubMed Web of Science ®Google Scholar
• Monga N, Tam C, Garside J, et al. Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: a systematic literature review. Crit Rev Oncol Hematol. 2021;158:103212.
   PubMed Web of Science ®Google Scholar
• Robak T, Jin J, Pylypenko H, et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(11):1449–1458.
   PubMed Web of Science ®Google Scholar
• Gressin R, Daguindau N, Tempescul A, et al. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. Haematologica. 2019;104(1):138–146.
   PubMed Web of Science ®Google Scholar
• Romaguera JE, Wang M, Feng L, et al. Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma. Cancer. 2018;124(12):2561–2569.
   PubMed Web of Science ®Google Scholar
• Albertsson-Lindblad A, Kolstad A, Laurell A, et al. Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. Blood. 2016;128(14):1814–1820.
   PubMed Web of Science ®Google Scholar
• Wang ML, Jain P, Lee HJ, et al. Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial. Blood. 2020;134(Supplement_1):3987.
   Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Christos P, et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018;132(19):2016–2025.
   PubMed Web of Science ®Google Scholar
• Yamshon S, Martin P, Shah B, et al. Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study. Blood. 2020;136(Supplement 1):45–46.
   Google Scholar
• Gine E, De La Cruz MF, Grande C, et al. Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): preliminary Results of Geltamo IMCL-2015 Phase II Trial. Blood. 2019;134(Supplement_1):752.
   Web of Science ®Google Scholar
• Le Gouill S, Morschhauser F, Chiron D, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood. 2021;137(7):877–887.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677–2684.
   PubMed Web of Science ®Google Scholar
• Gerson JN, Handorf E, Villa D, et al. Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. J Clin Oncol. 2019;37(6):471–480.
   PubMed Web of Science ®Google Scholar
• Cowan AJ, Stevenson PA, Cassaday RD, et al. Pretransplantation minimal residual disease predicts survival in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in complete remission. Biol Blood Marrow Transplant. 2016;22(2):380–385.
   PubMed Web of Science ®Google Scholar
• Kamdar M, Li H, Chen RW, et al. Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Adv. 2019;3(20):3132–3135.
   PubMed Web of Science ®Google Scholar
• Merryman RW, Edwin N, Redd R, et al. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv. 2020;4(5):858–867.
   PubMed Web of Science ®Google Scholar
• Kolstad A, Pedersen LB, Eskelund CW, et al. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years. Biol Blood Marrow Transplant. 2017;23(3):428–435.
   PubMed Web of Science ®Google Scholar
• Cheminant M, Robinson S, Ribrag V, et al. Prognosis and outcome of stem cell transplantation for mantle cell lymphoma. Expert Rev Hematol. 2015;8(4):493–504.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367(6):520–531.
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol. 2020;38(3):248–256.
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017;377(13):1250–1260.
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Gurion R, Raanani P, et al. Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials. Hematol Oncol. 2017;35(4):424–431. .
   PubMed Web of Science ®Google Scholar
• Rummel M, Knauf W, Goerner M, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: first results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). J Clin Oncol. 2016;34(15_suppl):7503.
   Web of Science ®Google Scholar
• Hilal T, Wang Z, Almader-Douglas D, et al. Rituximab maintenance therapy for mantle cell lymphoma: a systematic review and meta-analysis. Am J Hematol. 2018;93(10):1220–1226.
   PubMed Web of Science ®Google Scholar
• Ip A, Mato A, Intrator J, et al. COVID-19 Impact on Lymphoma patients’ clinical outcomes - an Observational Cohort Study. Blood. 2020;136(Supplement 1):6–7.
   PubMedGoogle Scholar
• Binder M, O’Byrne MM, Maurer MJ, et al. Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. Am J Hematol. 2017;92(8):752–758.
   PubMed Web of Science ®Google Scholar